Our next LGC Impact Award finalist entry was from Holly Milton and her team, who are improving how emerging synthetic opioids, like nitazenes, are detected in post-mortem samples, helping ensure drug-related deaths don’t go undetected. Read their full published research paper here: https://ow.ly/6utS50YQZx4 Learn more about our human drugs testing services and get in touch with the team: https://ow.ly/aX8t50YQZx3 #ScienceForASaferWorld #LGCProtects
LGC’s Post
More from this author
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
So happy to see Holly Milton and her LGC Human Drugs Testing team’s work recognised this year. Holly beautifully translated complex forensic research into a clear and compelling story about why this work matters. Why does it matter? Because improving the detection of emerging synthetic opioids can help strengthen forensic investigations, support public health and ultimately prevent drug-related deaths from going undetected.